Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."